The company focuses on developing and commercializing implantable tissue-engineered brain pathways to reconstruct lost connections due to brain degeneration or injury. Their lead clinical product is a tissue-engineered nigrostriatal pathway for Parkinson's disease, which specifically reconstructs brain pathways rather than just masking symptoms temporarily. Innervace was founded in 2018 in Philadelphia, Pennsylvania and aims to provide patients with access to technology that directly replaces lost connections in the brain.